Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records

By sjmartinez • May 12, 2023

Polito L, Shim J, Hurvitz SA, Dang CT, Knott A, Du Toit Y, Restuccia E, Sanglier T, Swain SM. Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records. JCO Oncol Pract. 2023 May 11:OP2200565. doi: 10.1200/OP.22.00565. Epub ahead of print. PMID: 37167571.

Tags: Hematology/Oncology, Publications

Understanding Barriers to Colon Cancer Screening Among Individuals Experiencing Housing Insecurity in Los Angeles

Burra A, Gonzales N, Jiang J, Zhang S, Obasi M, Eeraveni A, Garcia Jimenez M, Goldgar S. Understanding Barriers to Colon Cancer Screening Among Individuals[...]

Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy

Haidar AJ, Chen A, Chen JL, Al-Hashimi S, Ghaffari RS, Fung S, Silverstein J, Konecny GE, Tsui E. Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.[...]

Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion of Patients with Brain Metastases and Leptomeningeal Disease

Riano I, Velez MA, Pomares-Millan H, Blaquier J, Peshin S, Feldman J, Velazquez AI. Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion[...]